AstraZeneca Plc plans to conduct a global study to find the optimal interval between the two doses of its coronavirus vaccine. "The new trial will investigate a two-month gap between shots to determine whether it can provide better efficacy," chief executive Pascal Soriot told a group of European newspapers Tuesday. “You get a better efficiency if you get the second dose later," Soriot told the newspapers, including Italy’s La Repubblica. “We are going to do a study in the US and globally to use two-month dose interval to confirm that this is indeed the case." United Kingdom approved the vaccine, developed with the University of Oxford and AstraZeneca, last month with a 4-to 12-week dosing interval.

Source: Mint January 27, 2021 14:26 UTC